Due to the decision of new rights issue of SEK 60 M after the acquisition of the Icelandic company Zymetech, and the Extraordinary General Meeting to be held on April 14 for approval of the rights issue Enzymatica has changed dates for the announcement of its financial information.
Q1 Interim report: 18 April
Issue of the annual report 2015: at the latest 27 April
Annual General Meeting: 25 May
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: firstname.lastname@example.org
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.
Enzymatica's certified adviser is Erik Penser Bankaktiebolag.